Skip to main content
Premium Trial:

Request an Annual Quote

Imaxio Attains CSP Status for Agilent's SureSelect System for NGS

NEW YORK (GenomeWeb News) – Agilent Technologies said today that French biotech firm Imaxio has achieved Certified Service Provider status for the SureSelect Target Enrichment System for next-generation sequencing.

Imaxio was already a CSP for Agilent's microarray services and participated in comprehensive on-site training and passed a set of requirements demonstrating expertise and skill to receive CSP status for the SureSelect system, Agilent said. SureSelect is compatible with major NGS platforms, such as Illumina, Life Technologies' SOLiD, and Roche's 454.

Based in Lyon, France, Imaxio focuses on genomics and vaccine research and provides services that use microarray technology and next-generation sequencing for both DNA and RNA.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.